Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor

US11865167B2 · kind B2 · utility

Assignees

• Novartis AG · CH
• The Trustees of the University of Pennsylvania · US
• University of Pittsburgh—Of the Commonwealth System of Higher Education · US

Inventors

• Jennifer Brogdon · Cambridge, US
• Laura Alexandra Johnson · Ardmore, US
• Carl H. June · Yeadon, US
• Andreas Loew · Somerville, US
• Marcela Maus · Lansdowne, US
• John Scholler · Narberth, US
• Hideho Okada · Mill Valley, US

Key dates

• Filing date: Apr 12, 2019
• Grant date: Jan 9, 2024
• Expiry date: Mar 2, 2041

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/33
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention provides compositions and methods for treating diseases associated with expression of EGFRvIII. The invention also relates to chimeric antigen receptor (CAR) specific to EGFRvIII, vectors encoding the same, and recombinant T cells comprising the anti-EGFRvIII CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises an anti-EGFRvIII binding domain.